This project aims to develop an understanding of yet unknown molecular events involved in oncogenesis, specifically the role played by post-translational acetylation of the tumor suppressor p53 protein. Disruption of growth-arrest responses and apoptotic pathways by missense mutations of the p53 gene is known to confer a selective advantage to neoplastic clones and to render them refractory to several anti-neoplastic treatments. Such unresponsiveness is, at least partially, sustained by the fact that most of p53 mutants are incapable of binding to p53-specific DNA-binding sites and thus, of activating growth-regulatory genes. Direct gene therapy, by introduction of a normal p53 gene into tumor cells has been attempted but yielded inconclusive results, probably due to dominant negative activity(s) intrinsic to several p53 mutant proteins. Thus, the possibility of rescuing normal activity(s) from a p53 from a p53 mutant per se appears to attractive alternative approach. Studies showing that the DNA binding ability of p53 mutants can be reestablished in vitro by the addition of anti-p53 monoclonal antibodies, support this view and provide valuable evidence that the structure of p53 is flexible. I have now demonstrated that post-translational acetylation of p53 by the acetyl-transferase, P/CAF, restores sequence specific DNA-binding of p53 mutant proteins otherwise dysfunctional for binding to DNA. Furthermore, overexpression of P/CAF in transformed cell lines carrying mutations of the p53 gene rescues most phenotypes of transformed cells, including a normal morphotype and responsiveness to genotoxic agents, such as UV-irradiation. These findings implicate P/CAF as a crucial component of an intracellular pathway cascade which normally prevents oncogenesis. They also reveal the existence of a novel molecular mechanism whereby acetylation of p53, and perhaps of other regulatory proteins, micht determine the sensitivity of tumor cells to therapeutic agents. I propose here genetic and biochemical approaches to examine how P/CAF exerts its tumor-suppressive activity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
7R01CA083979-04
Application #
6514244
Study Section
Pathology B Study Section (PTHB)
Program Officer
Blair, Donald G
Project Start
1999-05-01
Project End
2004-02-29
Budget Start
2002-03-01
Budget End
2003-02-28
Support Year
4
Fiscal Year
2002
Total Cost
$210,041
Indirect Cost
Name
George Washington University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
City
Washington
State
DC
Country
United States
Zip Code
20052
Rodriguez, Olga Catalina; Choudhury, Sujatra; Kolukula, Vamsi et al. (2012) Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy. Cell Cycle 11:4436-46
Kirilyuk, Alexander; Shimoji, Mika; Catania, Jason et al. (2012) An intrinsically disordered region of the acetyltransferase p300 with similarity to prion-like domains plays a role in aggregation. PLoS One 7:e48243
Ullmann, Rebecca; Chien, Christopher D; Avantaggiati, Maria Laura et al. (2012) An acetylation switch regulates SUMO-dependent protein interaction networks. Mol Cell 46:759-70
Catalina-Rodriguez, Olga; Kolukula, Vamsi K; Tomita, York et al. (2012) The mitochondrial citrate transporter, CIC, is essential for mitochondrial homeostasis. Oncotarget 3:1220-35
Cheema, Amrita; Knights, Chad D; Rao, Mahadev et al. (2010) Functional mimicry of the acetylated C-terminal tail of p53 by a SUMO-1 acetylated domain, SAD. J Cell Physiol 225:371-84
Perez, Ricardo E; Knights, Chad D; Sahu, Geetaram et al. (2010) Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway. J Cell Physiol 225:394-405
Di Giovanni, Simone; Knights, Chad D; Rao, Mahadev et al. (2006) The tumor suppressor protein p53 is required for neurite outgrowth and axon regeneration. EMBO J 25:4084-96
Knights, Chad D; Catania, Jason; Giovanni, Simone Di et al. (2006) Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J Cell Biol 173:533-44
Fu, Maofu; Rao, Mahadev; Wang, Chenguang et al. (2003) Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 23:8563-75
Hirschler-Laszkiewicz, I; Cavanaugh, A; Hu, Q et al. (2001) The role of acetylation in rDNA transcription. Nucleic Acids Res 29:4114-24